drugset / Trial / NCT02574858
Study of the Safety of QRH-882260 Heptapeptide
NaSingle-groupOpen-labelOther
Summary
The purpose of this study is to evaluate the safety of orally administered QRH-882260, a topically administered Cy5-labeled heptapeptide specific for epithelial growth factor receptor (EGFR).
Timeline
- Start
- 2015-11
- Primary completion
- 2016-08
- Completion
- 2016-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QRH-882260 | Peptide | 1 mg | Oral |
| Subject | QRH-882260 | Peptide | 4.2 mg | Oral |
Indications
No indication recorded.